Efficacy and pharmacodynamics of herbal medicine in patients with metabolic phenotype of osteoarthritis
- 作者: Shirinsky I.V.1, Filatova K.Y.1, Shirinsky V.S.1
-
隶属关系:
- Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences
- 期: 卷 27, 编号 4 (2024)
- 页面: 981-986
- 栏目: SHORT COMMUNICATIONS
- URL: https://journals.rcsi.science/1028-7221/article/view/267916
- DOI: https://doi.org/10.46235/1028-7221-16878-EAP
- ID: 267916
如何引用文章
全文:
详细
High prevalence of the metabolic phenotype of osteoarthritis (MPOA) and unsatisfactory methods of its treatment necessitate the development of novel therapeutic approaches for this phenotype of OA. Turmeric preparations have a wide range of biological activity; their use in patients with MPOA can be effective and reduce the drug burden. In the present paper, we review our own published research findings on the effectiveness and pharmacodynamics of turmeric preparations in patients with MPOA. In the two studies, we evaluated the effects of two curcumin-containing parapharmaceuticals: Epigenorm Antivir (EA) and Curcumin. Forty-one women with MFOA were included in both studies. Twenty-three patients received EA at a daily dose of 1000 mg for 12 weeks, and 18 patients received curcumin from Evalar at a dose of 1000 mg for 8 weeks. The endpoints for both studies were VAS pain, dysfunction and other symptoms of OA measured using the KOOS scale. After 12 weeks of EA treatment, there was a 2.5-fold decrease pain levels. The decrease in pain was associated with an improvement in the patient’s daily and sports activities and quality of life. These effect sizes were classified as moderate to large according to Cohen. No adverse events were observed during the period of taking EA. Clinical improvement was associated with a decrease in the content of MS individual components: low-density lipoprotein cholesterol and triglycerides. The treatment caused a decrease in the level of systemic inflammation, as evidenced by a decrease in the concentration of TNFα, histamine, IL-18, C-reactive protein, and neopterin. The concentrations of IL-10 and adiponectin increased after treatment. In another study, treatment with curcumin for 4 weeks had an analgesic effect, improved measures of function and quality of life. Clinical improvement was associated with the reductions in serum levels of a number of proinflammatory cytokines, C-reactive protein, and lipids. Thus, the results of the pilot studies evaluating efficacy, safety, and pharmacodynamics of parapharmaceuticals EA and Curcumin in patients with MFOA indicate pleiotropic effects of the interventions. The findings provide a rationale for conducting larger, controlled, blind, randomized clinical trials.
作者简介
I. Shirinsky
Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences
编辑信件的主要联系方式.
Email: ivan.shirinsky@gmail.com
PhD, MD (Medicine), Leading Research Associate, Head of the Laboratory for Studying Multimorbidity of Rheumatic Diseases, Research Institute of Therapy and Preventive Medicine
俄罗斯联邦, 175/1 Boris Bogatkov St, Novosibirsk, 630089K. Filatova
Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences
Email: ivan.shirinsky@gmail.com
Junior Research Associate, Laboratory for Studying Multimorbidity of Rheumatic Diseases, Research Institute of Therapy and Preventive Medicine
俄罗斯联邦, 175/1 Boris Bogatkov St, Novosibirsk, 630089V. Shirinsky
Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences
Email: ivan.shirinsky@gmail.com
PhD, MD (Medicine), Professor, Leading Research Associate, Laboratory for Studying Multimorbidity of Rheumatic Diseases, Research Institute of Therapy and Preventive Medicine
俄罗斯联邦, 175/1 Boris Bogatkov St, Novosibirsk, 630089参考
- Алексеева Л.И., Таскина Е.А., Кашеварова Н.Г., Шарапова Е.П., Аникин С.Г., Стребкова Е.А., Короткова Т.А., Раскина Т.А., Зонова Е.В., Оттева Э.Н. Остеоартрит коленных суставов и метаболический синдром: новые подходы к терапии // Научно-практическая ревматология, 2018. Т. 56, № 2. С. 157-163. [Alekseeva L.I., Taskina E.A., Kashevarova N.G., Sharapova E.P., Anikin S.G., Strebkova E.A., Korotkova T.A., Raskina T.A., Zonova E.V., Otteva E.N. Knee osteoarthritis and metabolic syndrome: new approaches to therapy. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice, 2018, Vol. 56, no. 2, pp. 157-163. (In Russ.)]
- Ширинский В.С., Калиновская Н.Ю., Филатова Е.Ю., Ширинский И.В. Комбинированная терапия больных с метаболическим фенотипом остеоартрита: поисковое исследование // Медицинская иммунология, 2020. Т. 22, № 5. С. 933-942. [Shirinsky V.S., Kalinovskaya N.Yu., Filatova Е.Yu., Shirinsky I.V. Combination treatment of patients with metabolic phenotype of osteoarthritis: an exploratory study. Meditsinskaya Immunologiya = Medical Immunology (Russia), 2020, Vol. 22, no. 5, pp. 933-942. (In Russ.)] doi: 10.15789/1563-0625-CTO-2046.
- Ширинский И.В., Ширинский В.С., Филатова К.Ю. Эффективность и безопасность куркумина у пациентов с метаболическим фенотипом остеоартрита: пилотное исследование // Медицинская иммунология, 2023. Т. 25, No 5. С. 1099-1102. [Shirinsky I.V., Shirinsky V.S., Filatova K.Yu. Efficacy and safety of curcumin in patients with metabolic phenotype of osteoarthritis: A pilot study. Meditsinskaya Immunologiya = Medical Immunology (Russia), 2023, Vol. 25, no. 5, pp. 1099-1102. (In Russ.)] doi: 10.15789/1563-0625-EAS-2771.
- Boyanapalli S.S., Tony Kong A.N. “Curcumin, the king of spices”: epigenetic regulatory mechanisms in the prevention of cancer, neurological, and inflammatory diseases. Curr. Pharmacol. Rep., 2015, Vol. 1, pp. 129-139.
- Buhrmann C., Mobasheri A., Busch F., Aldinger C., Stahlmann R., Montaseri A., Shakibaei M. Curcumin modulates nuclear factor kappa B-mediated inflammation in human tenocytes in vitro: role of the phosphatidylinositol 3-kinase. Akt pathway. J. Biol. Chem.,2011, Vol. 286, no. 32, pp. 28556-28566.
- Englund M. Osteoarthritis, part of life or a curable disease? A bird’s-eye view. J. Intern. Med., 2023, Vol. 293, no. 6, pp. 681-693.
- Jackson G.L., Powers B.J., Chatterjee R., Bettger J.P., Kemper A.R., Hasselblad V., Dolor R.J., Irvine R.J., Heidenfelder B.L., Kendrick A.S., Gray R, Williams JW. The patient centered medical home. A systematic review. Ann. Intern. Med., 2013, Vol. 5, no. 158 (3), pp. 169-178.
- Madhu K., Chanda K., Saji M.J. Safety and efficacy of Curcuma longa extract in the treatment of painful knee osteoarthritis: a randomized placebo-controlled trial. Inflammopharmacology, 2013, Vol. 21, no. 2, pp. 129-136.
- Nakagawa Y., Mukai S., Yamada S., Matsuoka M., Tarumi E., Hashimoto T., Tamura C., Imaizumi A., Nishihira J., Nakamura T. Short-term effects of highly-bioavailable curcumin for treating knee osteoarthritis: a randomized, double-blind, placebo-controlled prospective study. J. Orthop. Sci., 2014, Vol. 19, pp. 933-939.
- PLOS Medicine Editors. Multimorbidity: Addressing the next global pandemic. PLoS Med., 2023, Vol. 20, no. 4, e1004229. doi: 10.1371/journal.pmed.1004229
- Roos E.M., Roos H.P., Lohmander L.S., Ekdahl C., Beynnon B.D. Knee Injury and Osteoarthritis Outcome Score (KOOS) – development of a self-administered outcome measure. J. Orthop. Sports Phys. Ther., 1998, no. 28, pp. 88-96.
- Zhao J., Liang G., Zhou G., Kunhao Y., Weiyi L. Efficacy and safety of curcumin therapy for knee osteoarthritis: A Bayesian network meta-analysis. J. Ethnopharmacol., 2024, Vol. 321, 117493. doi: 10.1016/j.jep.2023.117493.
补充文件
